Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket - Novartis (NY

iSpecimen Inc (NASDAQ:ISPC) shares rose 27.9% to $1.97 in pre-market trading after announcing a $4.5M acquisition of Foldlab AI assets. Novartis AG (NYSE:NVS) shares fell 12.7% to $139.56 following a failed clinical trial. Other stocks also moved significantly in pre-market trading.

Original reporting
Published Sep 8, 2026, 8:44 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 7:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$ISPC
Bullish
high confidence
Mentioned
$ISPC · $WDH · $DYN · $NVS
Relevance
6/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$ISPCBullishHigh
01

Why it matters

Key events include iSpecimen's AI asset acquisition, Waterdrop's upcoming earnings, Dyne's data presentation, and Novartis's trial miss, each driving distinct market reactions.

02

Market read

The mix of acquisition news, earnings preview, and clinical trial outcome provides immediate trading opportunities across biotech and pharma sectors.

03

What to watch

Regulatory review of the Foldlab AI assets could delay benefits; Novartis may have pipeline offsets.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

The article is a pre‑market mover roundup highlighting several stocks with notable price changes and upcoming catalysts.

Company-level read

Ticker impact

$ISPCBullishHigh confidence
Context

iSpecimen announced a $4.5 million acquisition of Foldlab AI assets, driving a 27.9% pre‑market jump.

Expected impact

Expect continued upside as the market digests the deal.

Evidence & confidence

Large percentage move on a concrete deal suggests strong short‑term buying pressure.

$WDHNeutralMedium confidence
Context

Waterdrop disclosed it will report its Q2 results on Sept. 8, prompting a 7.2% pre‑market gain.

Expected impact

Potential swing depending on earnings surprise.

Evidence & confidence

Upcoming earnings are a known catalyst but no results yet.

$DYNNeutralMedium confidence
Context

Dyne Therapeutics will present preclinical data for Duchenne muscular dystrophy candidates at a scientific meeting.

Expected impact

Possible upside if data exceeds expectations; downside risk if not.

Evidence & confidence

Pre‑clinical data releases are material for biotech stocks.

$NVSBearishHigh confidence
Context

Novartis reported its pelacarsen Phase III HORIZON trial missed the primary endpoint, sending the stock down 12.7% pre‑market.

Expected impact

Further declines expected until clarification on next steps.

Evidence & confidence

Phase III miss is a material event for a large pharma.

Market effects

AI acquisition highlights growing consolidation in biotech AI tools; trial failure may dampen lipid‑lowering sector sentiment.

US biotech and pharma stocks see mixed reactions; European markets largely unaffected.

Large‑cap pharma news (Novartis) could influence global lipid‑therapy outlook.

Counterpoint

ISPC's high valuation post‑deal may be overblown; investors could wait for integration details.

Key entities

  • iSpecimen Inc

    Biotech firm acquiring AI assets.

  • Foldlab AI

    AI models and software purchased by iSpecimen.

  • Novartis AG

    Pharma giant with failed Phase III trial.

Related articles

$NVSMed

Novartis wins FDA approval for Cosentyx in polymyalgia rheumatica

Novartis announced FDA approval for Cosentyx (secukinumab) to treat polymyalgia rheumatica in adults unresponsive to corticosteroids. The 150-mg dose showed 40.5% remission at Week 52 vs. 20.5% for placebo. This is Cosentyx's 11th U.S. indication. The approval follows positive Phase III trial results, with the drug demonstrating steroid-sparing effects. Novartis also noted ongoing regulatory reviews in other regions.

$NVSMed

Novartis Pharma AG: Novartis Cosentyx becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)

Novartis' Cosentyx (secukinumab) received FDA approval for treating polymyalgia rheumatica (PMR), marking its 11th US indication. The approval follows a Phase III trial where Cosentyx doubled sustained remission rates compared to placebo. Novartis aims to address the unmet needs of PMR patients, offering an alternative to long-term steroid use. The drug is already approved in the EU and under regulatory review in Japan.